Thomson Medical narrows H2 net loss to S$19.5 million on lower goodwill impairment, finance costs
The group’s loss per share has improved to S$0.00074, from S$0.00131 a year earlier
Thomson Medical, a healthcare operator, reduced its net loss for the second half of the year to S$19.5 million from S$34.7 million in the previous period. The company reported a 48.7% decrease in other operating expenses to S$61.3 million, down from S$119.4 million. A significant factor in this improvement was a reduction in goodwill impairment loss from S$75.1 million to S$15.2 million stemming from the acquisition of Far East Medical Vietnam.
Additionally, finance costs fell 14.7% to S$23.2 million due to lower interest rates. Revenue grew 5.8% year-over-year to S$207 million, up from S$195.6 million. Loss per share improved to S$0.00074 from S$0.00131 a year earlier. The company did not declare a dividend for FY2026, as it seeks to conserve cash for working capital and potential growth opportunities.
Revenue increased primarily due to higher intensity in Singapore, reduced discounts, and greater contributions from its oncology center in Malaysia. Vietnam's revenue rose due to higher patient volumes, though it was partially offset by an unfavorable exchange rate. For the full year, Thomson Medical reported a net loss of S$27.8 million, a 40.8% decrease from the S$47 million loss in FY2025.
The company expects to continue incurring losses over the next 12 months as it invests, expands, and transforms, but remains poised to seize emerging opportunities and achieve sustainable growth and value.
Written by urgent.news from The Business Times - Companies & Markets's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
